Clinical pharmacology of alosetron

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 13, Issue 2, 1999, Pages 70-76

  Gunput, M D ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; SEROTONIN; CARBOLINE DERIVATIVE; SEROTONIN ANTAGONIST;

ADULT; CLINICAL PHARMACOLOGY; CLINICAL TRIAL; COLON; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG HALF LIFE; ELECTROLYTE TRANSPORT; FEMALE; HUMAN; HUMAN EXPERIMENT; INTESTINE TRANSIT TIME; INTRAVENOUS DRUG ADMINISTRATION; IRRITABLE COLON; JEJUNUM; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PERCEPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN IRRITATION; SMALL INTESTINE ABSORPTION; STOMACH ACID SECRETION; STOMACH DISTENSION; WATER ABSORPTION; GASTROINTESTINAL TRANSIT; PATHOPHYSIOLOGY; PH; REVIEW;

CARBOLINES; COLONIC DISEASES, FUNCTIONAL; GASTROINTESTINAL TRANSIT; HUMANS; HYDROGEN-ION CONCENTRATION; RANDOMIZED CONTROLLED TRIALS; SEROTONIN ANTAGONISTS;

MLCS; MLOWN;

EID: 0033129381     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (25)

1. Talley NJ. 5-hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: Clinical implications. Aliment Pharmacol Ther 1990; 6: 273-89.
2. Gore S, Giolmore IT, Haigh CG, Brownless SM, Stockdale H, Morris AL. Colonic transit in man is slowed by ondansetron. (GR38032F): a selective 5-hydroxytryptamine receptor (type 3) antagonist Aliment Pharmacol Ther 1990; 4: 139-44.
3. 3 receptor antagonist, slows colonic transit in healthy man. Dig Dis Sci 1990; 35: 477-80.
4. Lèmbo T, Munakata J, Mertz H, et al. Evidence for the hypersensitivity of lumbar splanchnic afferents in irritable bowel syndrome. Gastroenterology 1994; 107: 1686-96.
5. 3-receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1993; 7: 175-80.
6. Fozard JR. Neuronal 5-HT receptors in the periphery. Neuropharma 1984; 23: 1473.
7. 3 receptor antagonists. Br J Clin Pharmacol 1994; 37: 525-30.
8. Orwin JM, Fozard JR. Blockade of the flare response to intradermal 5-hydroxytryptamine in man by MDL 72.222, a selective antagonist at neuronal 5-hydroxytryptamine receptors. Eur J Clin Pharmacol 1986; 20: 209-12.
9. Mayer EA, Raybould HR Role of visceral afferent mechanisms in functional bowel disorders. Gastroenterology 1990; 99: 1688-1704.
10. Fioramonti J, Frexinos J, Staumont G, Bueno L. Inhibition of the colonic motor response to eating by pinaverium bromide in irritable bowel syndrome patients. Fundam Clin Pharmacol 1988; 2: 19-27.
11. Lynn R, Friedman LS. Irritable bowel syndrome. New Eug J Med 1993; 26: 1940-5.
12. Thompson WG, Creed F, Drossman DA, Heaton KW, Mazzacca G. Functional bowel disorders and functional abdominal pain. Gastroenterol 1992; 5: 75-91.
13. 3 receptor antagonist. Br J Clin Pharmacol 1992; 33: 546p-547p.
14. 3 antagonist on gastrointestinal transit in normal healthy volunteers. Gastroenterology 1995; 108: A601.
15. Foster JM, Houghton LA, Whorwhell PJ. Alosetron slows colonic transit in patients with irritable bowel syndrome (IBS). Gastroenterology 1997; 112: A732.
16. Delvaux M, Louvel D, Mamet JP, Campos-Oriola R, Frexinos J. Effect of alosetron on response to colonic distension in patients with irritable bowel syndrome (IBS). Aliment Pharmacol Ther 1998; 12: 849-55.
17. 3 antagonist alosetron on basal and cholera toxin induced secretion in the human jejunum: a segmental perfusion study. Aliment Pharmacol Ther 1997; 11: 1109-14.
18. Zerbib F, Bruley des Varannes S, et al. Alosetron does not affect the visceral perception of gastric distension in healthy subjects. Aliment Pharmacol Ther 1994; 8: 403-7.
19. Pattee PL, Thompson WG. Drug treatment of the irritable bowel syndrome. Drugs 1992; 44: 200-6.
20. Read M, Read NW. Anal sphincter function in diarrhea: influence of loperamide. Clin Res Rev 1981; 1: 219-24.
21. Drossman DA, Li Z, Andruzzi E, et al. US Householder survey of functional gastrointestinal disorders. Dig Dis Sci 1993; 38: 1569-80.
22. Talley NJ. Spectrum of chronic dyspepsia in the presence of the irritable bowel syndrome. Scand J Gastroenterol 1991; 182: 7-10.
23. Talley NJ, Zinsmeister AR, Schleck CD, Melton LJ. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992; 102: 1259-68.
24. Johansen B, Bech K, BRL24924, a 5-hydroxytryptamine type 3 antagonist and gastric secretion of acid and pepsin in vivo. Digestion 1991; 48: 121-7.
25. McCullum RW. Cisapride: a new class of prokinetic drug. Am J Gastroenterol 1991; 86: 135-49.